التكنولوجيا وأخبارها بوابة الإمارات لتكنولوجيا المعلومات والإتصالات
–(– EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced the initiation of the Papa Giovanni XXIII Hospital sponsored study of siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, for the treatment
of patients with COVID-19 who have developed serious respiratory complications
(Siltuximab In SeriousCOVID-19; SISCO Study). Ergomed plc (LSE: ERGO), a company
focused on providing specialized services to the pharmaceutical industry, is providing
clinical research services for the study.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20200318005218/en/
Professor Alessandro Rambaldi, MD, PhD, Papa Giovanni XXIII Hospital, Bergamo, Italy,
Study Sponsor-Investigator and Director of the Hematology Unit and Department of
Oncology and Hematology, said: “The team at Papa Giovanni XXIII Hospital are thankful to
EUSA Pharma for the supply of siltuximab for compassionate use in patients with serious
complications of COVID-19 and the opportunity to generate data to understand the
potential for IL-6 blockade in these patients. The SISCO Study will allow us to generate
credible data as evidence to guide future treatment and research decisions and we look
forward to publication of these data as quickly as possible. The Hospital is in a very difficult
emergency situation and rapid collection and analysis of data by way of a case-control
study will provide much needed information to help address this critical situation and
appropriately guide the use of medicines in an off-label situation.”
Lee Morley, Chief Executive Officer, EUSA Pharma, said: “We are delighted to support this study to investigate the potential for siltuximab to help patients severely ill as a result of
COVID-19. Following the release of initial data from China suggesting a role of IL-6 in the development of Acute Respiratory Distress Syndrome as a result of COVID-19, EUSA
Pharma was pleased to assist Papa Giovanni XXIII Hospital with the supply of siltuximab under compassionate use and to support the collection, analysis and publication of initial
outcome data from this series of patients. We look forward to working further with the Hospital as well as Italian and Worldwide Regulatory Authorities, and other research
bodies to fully understand the potential of siltuximab at this critical time in the global pandemic.”
About the SISCO Study
Sponsored by the Papa Giovanni XXIII Hospital, the SISCO Study is an observational case-control trial of siltuximab, a chimeric monoclonal antibody targeting human interleukin (IL)-6, for the treatment of patients infected with COVID-19 who develop serious respiratory complications.
The study represents the data collection and analysis of a series of patients treated under an ongoing emergency compassionate use protocol. The study will investigate two cohorts retrospectively, hospitalised patients prior to admission to an intensive care unit (ICU) or patients already requiring intensive care, and will compare to matched controls. Primary endpoints are reduction in the need of invasive ventilation, time spent in ICU or 30-day mortality.
Emerging evidence suggests that exacerbated production of the inflammatory cytokine IL-6 is associated with the severity of COVID-19 related pulmonary pathology associated with Acute Respiratory Distress Syndrome (ARDS). Therefore, direct targeting of this cytokine may improve clinical outcomes in these critically ill patients.
This study will provide important data to inform future clinical studies, discussions on which are ongoing, to further investigate the efficacy of siltuximab in patients with COVID-19 who develop serious respiratory complications
